FDA Adverse Event Injury Summary report: N

STELLAREX 0.035 OTW DRUG-COATED ANGIOPLASTY BALLOON

MDR report key: 8705200 · Received June 17, 2019

Report

Report Number
3009784280-2019-00402
Event Type
Injury
Date Received
June 17, 2019
Date of Event
April 19, 2018
Report Date
April 19, 2018
Manufacturer
SPECTRANETICS
Product Code
ONU
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
BE
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

ADVERSE EVENT, OUTCOMES TO ADVERSE EVENT: THE PATIENT REQUIRED REVASCULARIZATION OF THE TARGET LESION. THIS IS BEING REPORTED AS A FOLLOW-UP TO THE CLINICAL STUDY. TESTS/LABORATORY DATA AND DATES: PATIENT INFORMATION REGARDING RELEVANT TESTS/LABORATORY DATA IS UNKNOWN. THIS INFORMATION WAS NOT AVAILABLE FROM THE FACILITY. UDI #, PMA/510K #: UDI AND PMA NUMBERS ARE NOT APPLICABLE. THIS DEVICE WAS USED IN CLINICAL APPLICATION PRIOR TO BEING AVAILABLE IN THE US. REPORT SOURCE: FOREIGN- (B)(6) / STUDY NAME: (B)(6), PATIENT ID # (B)(6). DEVICE EVALUATED BY MFR: DURING THE INDEX PROCEDURE, THE PRODUCT WORKED AS INTENDED, THUS NO PRODUCT EVALUATION WAS REQUIRED. PER THE IFU, RESTENOSIS IS LISTED AS A POTENTIAL COMPLICATIONS/ADVERSE EVENTS.

Description of Event or Problem · 1

IT WAS REPORTED THROUGH A CLINICAL STUDY THAT DURING THE INDEX PROCEDURE ON (B)(6) 2015, TWO STELLAREX CATHETERS WERE USED TO TREAT THE TARGET LESION OF THE RIGHT MID SFA. APPROXIMATELY 37 MONTHS POST INDEX PROCEDURE, THE PATIENT EXPERIENCED RESTENOSIS. A SUCCESSFUL REVASCULARIZATION OF THE TARGET LESION WAS PERFORMED ON (B)(6) 2018. THE PHYSICIAN INDICATED THIS IS NOT RELATED TO THE STUDY DEVICE OR PROCEDURE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
498466 STELLAREX 0.035 OTW DRUG-COATED ANGIOPLASTY BALLOON DCB PTA CATHETER ONU SPECTRANETICS A35DC06008013IO 14M1360802

Patients

Seq Age Sex Outcome Treatment
1 53 YR Hospitalization| R